Actuate Therapeutics Inc (ACTU )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ACTU
- Company Actuate Therapeutics Inc
- Price $1.44
- Changes Percentage -13.25
- Change -0.22
- Day Low $1.44
- Day High $1.62
- Year High $9.35
- Year Low $1.58
- Market Cap $43,545,051
- Price Avg 50 EMA (D) $2.48
- Price Avg 200 EMA (D) $5.21
- Exchange NASDAQ
- Volume 82,042
- Average Volume 144,814
- Open $1.61
- Previous Close $1.66
- EPS -0.98
- PE -1.86
- Earnings Announcement 2026-08-13 04:00:00
- Shares Outstanding $23,925,852
Company brief: ACTUATE THERAPEUTICS INC (ACTU )
- Healthcare
- Biotechnology
- Mr. Daniel M. Schmitt
- https://actuatetherapeutics.com
- US
- N/A
- 08-13-2024
- US0050831009
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.